Pantothenate kinase–associated neurodegeneration (formerly Hallervorden-Spatz syndrome), the most prevalent form of neurodegeneration with brain iron accumulation, is a rare degenerative brain disease characterised by predominantly extrapyramidal dysfunction resulting from mutations in the \textit{PANK2} (pantothenate kinase 2) gene. Using DNA mutation analysis, the authors identified a novel missense mutation (P354L) in exon 4 of the \textit{PANK2} gene in an adolescent with classic pantothenate kinase–associated neurodegeneration. DNA-based diagnosis of pantothenate kinase–associated neurodegeneration plays a key role in determination, and can make the diagnosis more simply, directly, and economically because it obviates the need for unnecessary biochemical tests. Once pantothenate kinase–associated neurodegeneration–like symptoms are identified, mutation analysis and target screening for the family of the proband can provide efficient and accurate evidence of pantothenate kinase–associated neurodegeneration inheritance.

**Introduction**

Pantothenate kinase–associated neurodegeneration (PKAN) is an autosomal recessive degenerative brain disease characterised by brain iron accumulation due to \textit{PANK2} gene mutation.\(^1\) The \textit{PANK2} gene, located at chromosome 20p13, is responsible for the encoding of the mitochondrial enzyme pantothenate kinase, essential for coenzyme A (CoA) biosynthesis, and fat and carbohydrate metabolism. It is uncertain as to how the lack of functional pantothenate kinase causes the symptoms of PKAN. Recent research has hypothesised that with the decrease in the amount of functional pantothenate kinase, phosphopantothenate falls, resulting in cysteine accumulation in the globus pallidus.\(^2\) Cysteine, itself cytotoxic, will undergo rapid auto-oxidation in the presence of iron, resulting in free radical production causing extensive damage to the basal ganglia, the region of the brain with the highest relative amount of non-heme iron.\(^3\) Conventionally, PKAN is categorised into two types—classic and atypical—by the age of onset, rate of disease progression, clinical and radiological features (Table).\(^4\) Mutations identified to date in the \textit{PANK2} gene include aberrant splicing, missense, and nonsense mutations. Over 100 mutations have been documented worldwide, and the correlation between the types and loci of mutations, and phenotypes of PKAN patients is now being extensively studied.\(^5,6\)

We report two children with a clinical diagnosis of Hallervorden-Spatz syndrome, one of whom was found to have a novel missense mutation of the \textit{PANK2} gene.

**Case reports**

**Case 1**

This patient was the second child of non-consanguineous Chinese parents. The antenatal, perinatal, and developmental history was unremarkable. There was no family history of neurological disease. She presented to us at the age of 4.5 years with a 2-year history of frequent falling and a hand tremor. She progressively regressed with increasing generalised dystonia, spasticity, and loss of the ability to talk, stand, walk, and write by the age of 8 years. L-dopa and clonazepam were given with no effect. At the age of 9 years, generalised seizures developed after an episode of hypoxic ischaemic encephalopathy subsequent to cardiac arrest due to sputum retention and choking. She was profoundly handicapped with intractable seizures despite supportive treatment with carbamazepine, clonazepam, and phenobarbital. She had frequent episodes of aspiration pneumonia and subsequently developed septicemia and acute renal failure at the age of 14 years in 1995. Magnetic resonance imaging (MRI) of the brain done in 1991 when she was 11 years of age reported hypointensity in T1- and T2-weighted images of the globus pallidus, probably due...
to increased iron deposition (Fig 1a). A retrospective review of the scan in 1995 confirmed the ‘eye of the tiger’ sign. No molecular studies were available.

Case 2
This patient was the third child of non-consanguineous Chinese parents. His developmental history was unremarkable. There was no family history of neurological diseases. His father died from lung cancer at the age of 50 years. He presented at the age of 12 years with a 2-year history of easy falling, tiptoe gait, slurring speech, and clumsiness along with poor handwriting and deterioration in his school performance. Mild upper limb dystonia was found during the initial examination. Investigations including a blood smear, liver and renal function tests, serum copper and ceruloplasmin levels, a lipid profile, serum uric acid, lactate and pyruvate levels; urine amino acids/organic acids were all normal. His cerebrospinal fluid was normal with no elevation in immunoglobulin G and no oligoclonal band. A computed tomographic scan and MRI of the brain were reported as normal. An ophthalmological examination showed no abnormalities. Severe dystonia gradually developed, affecting initially the upper limbs, then the lower limbs, neck, trunk, eyelids, mouth, and larynx in subsequent years. Chorea-thetosis of the upper limbs and mouth was also present. Magnetic resonance imaging of the brain was repeated in 1995 when he was 16 years of age and it showed the ‘eye of the tiger’ sign in the globus pallidus (Fig 1b). A diagnosis of Hallervorden-Spatz disease was made. He was treated with a combination of various drugs including L-dopa, trihexyphenidyl, baclofen, benzodiazepam, and tetrabenazine with very little effect. He refused a therapeutic trial of intrathecal baclofen. At the age of 22 years, his mobility deteriorated rapidly and he became wheelchair-bound. He developed an acute left-sided hemiparesis as a result of cervical cord compression secondary to C4,5 intervertebral disc extrusion so an anterior spinal fusion was performed. At the age of 24 years, he developed repeated vomiting with gastric distension and later developed a volvulus of the stomach. To relieve this, a gastro-jejunostomy was done in August 2003. Poor feeding and repeated vomiting continued and a barium swallow showed a dilated oesophagus with reduced oesophageal

<table>
<thead>
<tr>
<th>Feature</th>
<th>Classic PKAN</th>
<th>Atypical PKAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Onset of symptoms</td>
<td>Early, within first decade after birth or early adolescence</td>
<td>Second or third decade after birth</td>
</tr>
<tr>
<td>Progression of disease</td>
<td>10 years after onset</td>
<td>15-40 years after onset</td>
</tr>
<tr>
<td>Neurological symptoms</td>
<td>Gait abnormalities, extrapyramidal dysfunction such as dystonia and choreathetosis; corticospinal tract involvement</td>
<td>Speech disorders, extrapyramidal dysfunction such as dystonia and rigidity</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Rare</td>
<td>Depression, personality splits (30% of cases), obtrusive obsessions and compulsions</td>
</tr>
<tr>
<td>Retinitis pigmentosa or optic atrophy</td>
<td>Often (68%)</td>
<td>Rare</td>
</tr>
<tr>
<td>Magnetic resonance imaging/radiographic evidence</td>
<td>‘Eye of the tiger’ sign: hypointensity with central hyperintensity in the globus pallidus</td>
<td>‘Eye of the tiger’ sign: hypointensity with central hyperintensity in the globus pallidus</td>
</tr>
</tbody>
</table>

Mutational analysis of the PANK2 gene was performed as described in a previously published report. Sequencing revealed that the proband was homozygous for a novel missense mutation in exon 4 of the PANK2 gene (Fig 2a). The mutation, c.1391C>T, changed codon 464 of the PANK2 gene from CCA to CTA. The corresponding amino acid change was P354L according to Zhou et al or P464L according to conventional nomenclature. The amino acid change was a non-conservative change and this mutation was not identified in 100 normal chromosomes using direct DNA sequencing. The mother was heterozygous for c.1391C>T (Fig 2b). Pathogenicity of this mutation can be confirmed by in-situ mutagenesis, in-vivo expression, and functional analysis of the PANK2 mutant.

Discussion

Identification of the mutation in the PANK2 gene of the proband is significant when trying to distinguish between common neurodegeneration with brain iron accumulation (NBIA) and PKAN. The latter is a form of NBIA seen in people with PANK2 gene mutations. Hayflick et al reported a striking one-to-one correlation between the MRI ‘eye of the tiger’ sign and the presence and absence of PANK2 mutations. Baumeister et al, however, found that the ‘eye of the tiger’ sign may not be a reliable disease marker over the course of the disease in PKAN. In a recent study, Hartig et al also reported no strict correlation between the ‘eye of the tiger’ sign and PANK2 mutations. In case 2, the radiographic finding was not evident until a repeated MRI examination revealed the ‘eye-of-the-tiger’ sign 4 years after the onset of symptoms. The initially normal MRI finding, coupled with the absence of retinopathy, proves that ophthalmological and radiological signs of PKAN may not be conspicuous during the early stages. Perhaps clinical features are not sufficient for making an accurate diagnosis of PKAN, as people with common NBIA or hypoprebetaproteinaemia, acanthocytosis, retinopathy, pallidal degeneration (HARP) syndrome also display similar neurodegenerative signs and symptoms. In our case, the diagnosis of PKAN could only be made after repeated MRI examinations and was confirmed by the DNA analysis. The HARP syndrome is known to be allelic with PKAN, hence the employment of tests for red blood cell acanthocytosis and serum lipoprotein profiles play a significant role in differentiating between these two diseases.

These two patients had very similar clinical features but differed significantly in the onset of motor dysfunction, the pace of progression, and their severity. Case 1 had a very early onset of symptoms at the age of about 2 years and lost all skills within 6 years. Her disease progressed rapidly and was further complicated by a hypoxic ischaemic brain insult. Case 2 had a later onset of symptoms, at the age of 10 years, with slow progression until the age of 22 years when he developed secondary complications due to severe dystonia.

Dystonia is a common clinical feature among PKAN patients. Its severity compounds the progression of the disease and often causes serious complications. In our cases, the administration of baclofen, trihexyphenidyl, L-dopa and tetrabenazine did not alleviate the dystonia. The patient in case 2 suffered from severe cervical myelopathy 9 years after the onset of symptoms. He also developed a volvulus of the stomach requiring surgical correction, after 12 years. While the myelopathy can be attributed to severe dystonic movements of the neck, no specific reason, or linkage, has been identified for the occurrence of the volvulus of the stomach. Nonetheless, it is worth noting that as the disease progresses, secondary complications varying in severity will appear, probably resulting from extrapyramidal dysfunction, suggesting the need for early detection and more aggressive treatment of complications. Both of our patients died eventually of the complications of neurodegeneration.

Pigmentary degeneration is said to be a common feature of PKAN. However, Egan et al in his report on the neuro-ophthalmologic and electroretinographic (ERG) findings in genetic and neuroimaging confirmed cases of PKAN showed that only four of 10 examined patients had a pigmented retinopathy, none had optic atrophy and all of them

---

**FIG 2. Electropherogram for (a) homozygous c.1391C>T, and (b) heterozygous c.1391C>T**

The mutated codon is underlined.
showed some type of ocular motility disorder related to the tectal mid-brain. Of 16 patients, 11 had abnormal ERGs ranging from mild cone abnormalities to severe rod-cone dysfunction.

Due to the uncertainty surrounding the mechanism governing PKAN, medical treatments have so far only been aimed at palliation of the symptoms. In both our cases, baclofen, trihexyphenidyl and L-dopa were administrated to relieve the dystonia, but to no avail. The patients showed no significant improvements and severe dystonia gave rise to feeding problems, repeated aspiration and choking, and even myelopathy and gastric volvulus. Therapies are based on hypotheses of pathogenesis, and potential therapies are aimed at addressing low levels of CoA in mitochondria, oxidative stress, and iron overload. Use of compounds such as phosphopantothenate and fatty acids have been experimented with to increase the CoA levels in mitochondria. Possible therapies also include anti-oxidants (idebenone, coenzyme Q, alpha-tocopherol), which are believed to be able to relieve oxidative stress in the basal ganglia and retina. Nonetheless, drugs such as idebenone have been found to enhance superoxide formation and, in cases of atypical PKAN use of these has reportedly led to a worsening of symptoms.

On retrospectively reviewing these cases, we have come up with the following recommendations regarding the diagnosis of PKAN. Vigilance in searching for radiological and ophthalmologic abnormalities is of the utmost importance for diagnosis, although these may be absent during the early stages. Mutation analysis of the PANK2 gene should also be done at an early stage in children and adolescents with typical clinical features of PKAN even in the absence of the ‘eye of the tiger’ sign. Family screening for the heterozygous state and prenatal diagnosis are recommended, as PKAN is a severe mutation-caused adolescent neurodegenerative disease. Finally, to rule out HARP, a full lipid test is recommended to distinguish between suspected cases of PKAN and HARP.

Conclusion

While it is accepted that PKAN is caused by mutations in the PANK2 gene, genotype-phenotype correlations have not been established due to the small number of comparable cases. Due to the difficulty in identifying PKAN, it is possible that many cases have either been overlooked or mistakenly classified as common NBIA or idiopathic neurodegenerative diseases. Nonetheless, with the known association between PANK2 mutations and PKAN, and the list of clinical, radiographical, and molecular evidence available, the identification of PKAN should now be made more easily and more accurately.

Acknowledgement

The authors would like to express their gratitude to Mr Simon Chow for his assistance in laboratory work on molecular studies and his participation in literature research.

References